We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Test for Chlamydia Antigen Antibodies Optimized

By LabMedica International staff writers
Posted on 07 May 2019
Trachoma, resulting from repeated infection with the bacterium Chlamydia trachomatis (Ct), is the leading infectious cause of blindness. More...
Trachoma is targeted for elimination as a public health problem by 2020.

Serological surveillance for trachoma could allow monitoring of transmission levels in areas that have achieved elimination targets. Platforms that allow testing in basic laboratories or testing of easy-to-manage samples such as dried blood spots would contribute to the feasibility of serologic testing.

An international team of scientists led by the Centers for Disease Control and Prevention (Atlanta, GA, USA) collected blood from 506 1 to 12-year-olds in two villages in Kongwa district, Tanzania. The blood was tested for antibodies against the antigen Pgp3. Whole blood, plasma, and dried blood spots (DBS) were tested in laboratory and field settings using a cassette-enclosed Pgp3 lateral flow assay (LFA-cassette) and a pared-back “dipstick” assay (LFA-dipstick). DBS were also tested with a bead-based multiplex assay (MBA). Pooled ocular swab testing for Ct infection was performed using the GeneXpert CT/NG cartridge.

In the field evaluation of LFA-cassette using whole blood, the percent positive was 42.5% and the sensitivity was 84.2%. In the field evaluation of LFA-cassette using plasma, the percent positive was 48.4% and the sensitivity was 94.7%. The percent agreement between LFA-cassette and LFA-dipstick was 93.8%. The percent agreement between the MBA and each LFA format and sample type ranged from 92.3% to 94.7%. The percent positive by MBA was 45.5%, and the sensitivity was 94.7%. Interrater agreement between an expert rater and three different raters in field and laboratory settings was uniformly good.

The authors concluded that despite the minor differences in individual tests run, there were no significant differences in the percentage of positive samples as determined by MBA or any LFA tests. The data suggest that the LFA, in any number of iterations, and MBA could potentially be used interchangeably in a population-level, programmatic setting based on the program needs. The study was published in the April 2019 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Centers for Disease Control and Prevention


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.